Business Wire

IBSA

Share
The IBSA Group Relies on Sailing: The New Three-year Project, Halfway Between Sports Challenge and Social Sustainability, About to Be Launched

Challenge, resilience, courage, nature, innovation. These are the keywords that characterise Sailing into the Future. Together , the new international project that sees IBSA (Institut Biochimique SA) the protagonist of a new three-year enterprise, which starts in 2022, albeit with a long-term vision.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005863/en/

The project we are launching today is a real sporting endeavour, which sees us compete in some of the world’s most prestigious and challenging regattas”, stated Arturo Licenziati, President, CEO and Founder of IBSA . “This new project, however, is not only an ocean crossing, but also an opportunity to tell the values ​​of IBSA, increasing its visibility around the world. In fact, IBSA is today an international company that maintains a vision that is always aimed at the future and ready to face challenges that go well beyond the therapeutic and personal care areas ”.

Founded in 1945 and headquartered in Lugano (Switzerland), IBSA is a leading scientific, economic and industrial reality in the pharmaceutical sector, thanks to the design outlined by Arturo Licenziati. A multinational company employing 2,000 people – including headquarters, subsidiaries and production sites – IBSA is present with its products in over 90 countries on 5 continents, with 16 subsidiaries located in Europe, China and the United States and with a turnover of over CHF 700 million.

Innovating by keeping people at the core of our ecosystem, without ever setting limits: those are the horizons of the IBSA Group, which has always been inspired by the desire to go further ”, explained Licenziati . Sailing into the future. Together is a metaphor for our corporate history, but also a wish to grow and change, to find new means to offer health, well-being and new perspectives for the communities within which we operate, through social and environmental sustainability ”.

The project Sailing into the Future. Together engaged a team of great experience and sporting talent, involved right from the design and building phase of an innovative Class40 boat that will be led by Alberto Bona , the skipper who has been entrusted with the task of transforming this undertaking into a success.

The Route du Rhum is the first stage of a three-year project: it’s one of the most challenging solo regattas in the world, as well as one of the most popular events in international ocean sailing. The project relies on a competent and greatly experienced team, while the conceptual design of the boat and its construction are entrusted to a successful duo: thus, we have all the credentials to put a winning boat in the water. The further challenge will be to make the most of the time available after the July launch, and carry out the in-water test part to make it reliable and performing ”, commented Alberto Bona . “Naturally, I thank our sponsor IBSA, with which I share the taste for the challenge, for continuous improvement, and the desire to break through new horizons. IBSA has chosen sailing to represent strength, determination, innovation, but also to raise awareness about a greater respect for nature, with a view to sustainability.

Beyond sport, and in a broader perspective, sailing is part of a path that brings the Company ever closer to the topic of sustainability , promoting respect for nature and the environment, but also to a new sensitivity and awareness about issues of collective responsibility , with activities in favour of people in difficulty or with disabilities.

As part of this project, we decided to be a partner of some nautical clubs, in order to support inclusive sailing initiatives. We started a collaboration with the Yacht Club of Punta Ala (GR), to which we donated two boats for disabled children, to involve them in experiences in close contact with the sea, enabling them to navigate with accessible boats and compete in integrated races ”, explained Giorgio Pisani, Vice President Southern Europe and Project Leader . “The goal is to create an actual inclusion of the disabled on the competition field, promoting social integration as well as opportunities for dialogue, interaction and mutual understanding, thus helping break down barriers and differences ”.

The Company will also receive a prize during the award ceremony of the first edition (2022) of the Sport for Nature Awards – to be held today, March 17, 2022 – an event that aims to celebrate the “sport with a green soul”.

The award Azienda per il sociale: IBSA per la vela inclusiva (“Company for social initiatives: IBSA for inclusive sailing”) will be assigned precisely for raising awareness in favour of social and environmental sustainability through the values ​​of sport, and in particular of sailing, as a means for social inclusion.

To narrate all the phases of the project Sailing into the Future. Together and accompany its development, the new website www.ibsasailing.com was created, also available in Italian and French . From here, it will be possible to follow the journey of skipper Alberto Bona, find out more about the Route du Rhum , the team and the new Class40 boat, that will set sail on November 6 from Saint-Malo, headed towards the island of Guadeloupe. In addition, the site will host photo and video content and news relating to IBSA’s social responsibility initiatives.

IBSA

IBSA (Institut Biochimique SA) is a multinational pharmaceutical Swiss Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.

Link:

ClickThru

Social Media:

https://www.facebook.com/ibsapharma

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release

The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c

GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release

Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and

Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse

Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release

Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye